Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus BioSciences Inc.

www.coherus.com

Latest From Coherus BioSciences Inc.

Biocon And Mylan Prime Pegfilgrastim Expansion

Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.

Regulation Biosimilars

Biocon-Mylan Prime Pegfilgrastim Market Expansion

Biocon-Mylan’s sBLA approval for pegfilgrastim made at a new Indian site gets FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.

Policy & Regulation Biosimilars

Lupin’s Karkaria Addresses Biosimilars Pushback

Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.

Biosimilars Strategy

Lupin’s Karkaria On Biosimilars Pushback And Interchangeability

Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.

 

Commercial Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • BioGenerics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Coherus BioSciences Inc.
  • Senior Management
  • Dennis Lanfear, Chmn., Pres. & CEO
    Jean-Frederic Viret, PhD, CFO
    Vladimir Vexler, PhD, CSO
    Barbara K Finck, MD, Acting CMO
    Vince Anicetti, COO
    Erik Wiberg, EVP, Corp. Dev.
  • Contact Info
  • Coherus BioSciences Inc.
    Phone: (800) 794-5434
    333 Twin Dolphin Dr., Ste. 600
    Redwood City, CA 94065
    USA
UsernamePublicRestriction

Register